NCT01842139View on ClinicalTrials.gov

Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

December 5, 2011

Primary Completion Date

February 2, 2015

Study Completion Date

March 31, 2018

Conditions
Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions
BIOLOGICAL

basiliximab

Given IV

BIOLOGICAL

WT1 126-134 peptide vaccine

Given SC

DRUG

Montanide ISA 51 VG

Given SC

DRUG

poly ICLC

Given SC

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

60637-1470

University of Chicago, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT01842139 - Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission | Biotech Hunter | Biotech Hunter